$1000 Invested In TG Therapeutics 5 Years Ago Would Be Worth This Much Today
Subdued Growth No Barrier To TG Therapeutics, Inc. (NASDAQ:TGTX) With Shares Advancing 29%
TG Therapeutics Currently Up Seven Consecutive Days, On Track for Longest Winning Streak Since September 2020 -- Data Talk
TG Therapeutics (NASDAQ:TGTX) Delivers Shareholders Solid 15% CAGR Over 5 Years, Surging 6.6% in the Last Week Alone
Insider Sale: Director Sagar Lonial Sells 25,933 Shares of TG Therapeutics Inc (TGTX)
TG Therapeutics(TGTX.US) Director Sells US$432.89K in Common Stock
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises
Express News | Calstrs: Decided to Vote Against Laurence Charney, Yann Echelard, Kenneth Hoberman, Daniel Hume, Sagar Loniel, Michael Weiss at TG Therapeutics' AGM
TG Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
(TGTX) - Analyzing TG Therapeutics's Short Interest
TG Therapeutics to Participate in the Jefferies Global Healthcare Conference
Express News | TG Therapeutics Discloses Presentations For Post-marketing Studies Being Undertaken For BRIUMVI (Ublituximab-xiiy) In Patients With Relapsing Forms Of Multiple Sclerosis At 2024 Consortium Of Multiple Sclerosis Centers Annual Meeting
TG Therapeutics Announces Presentations for BRIUMVI (Ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting
TG Therapeutics (NASDAQ:TGTX) Seems To Use Debt Quite Sensibly
TG Therapeutics Announces Schedule of Upcoming Presentations for BRIUMVI (Ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting
Viking, CRISPR, Intellia Among Potential M&A Targets: Wells Fargo
Peering Into TG Therapeutics's Recent Short Interest
TG Therapeutics Under Pressure: Navigating the Perils of Government Contracts and Compliance Hurdles
TG Therapeutics | 10-Q: Quarterly report
New Forecasts: Here's What Analysts Think The Future Holds For TG Therapeutics, Inc. (NASDAQ:TGTX)
No Data